Phase 2 Lung Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Adults aged 18 or older (male or female)
- People who have been diagnosed with non-small cell lung cancer (a type of lung cancer), confirmed through a tissue or cell sample
- People who have at least one measurable cancer lesion in the brain, as assessed using a specific measurement standard called RANO-BM
- People whose tumour tissue or blood sample shows a specific gene change called an EGFR mutation
- People who have a good general level of physical functioning, rated 0 or 1 on a standard scale used by doctors (called ECOG PS)
- People with a life expectancy of more than 12 weeks
- People who have not previously received any systemic (whole-body) anti-cancer treatment for their lung cancer that has spread to other parts of the body
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose lung cancer is not of the adenocarcinoma type — for example, those with squamous cell lung cancer or a mixed type
- People who are expected to receive other anti-cancer treatments during the study, apart from the study drug
- People who have previously received systemic (whole-body) anti-cancer treatment
- People who have received certain recent treatments, including: radiation to more than 30% of bone marrow or a large area of the body within 4 weeks before starting the study drug; major surgery within 4 weeks before starting the study drug, or major surgery planned during the study (with some exceptions); certain medications that strongly affect a liver enzyme called CYP3A4 taken within 7–21 days before starting the study drug; certain traditional Chinese medicines with anti-cancer effects taken within 2 weeks before starting the study drug or expected to be needed during the study; participation in another clinical trial and receipt of an experimental drug or device within 4 weeks or 5 half-lives before starting the study drug; or other anti-cancer drugs taken within 14 days before starting the study drug
- People who have a history of another type of cancer, or who currently have another cancer at the same time
- People who still have significant side effects from previous cancer treatment that have not settled down to a mild level (with the exception of hair loss or certain nerve-related side effects from platinum-based chemotherapy)
- People who have a history of a lung condition called interstitial lung disease, lung inflammation caused by drugs or radiation that required steroid treatment, or who currently show signs that may suggest this type of lung condition
- People with serious problems affecting the digestive system that may interfere with taking, absorbing, or processing the study drug
- People with a recently active digestive disease (confirm with trial site)
- People who are prone to bleeding or have active bleeding, or who have had a significant bleeding event (grade 3 or above on a standard medical scale) in the 28 days before starting the study drug
- People with a clinically significant heart rhythm problem or a prolonged electrical interval in the heart (called QT interval), including specific conditions such as a QTc measurement above 470 ms on a resting heart tracing, complete left bundle branch block, third-degree heart block, a genetic condition called long QT syndrome, seriously low potassium levels, or current use of medications known to prolong the QT interval
- People whose bone marrow, liver, kidneys, or other organs are not functioning at a sufficient level
- People who have had an active blood clot in a vein in the past 6 months
- People with a known active hepatitis B infection, hepatitis C infection, or HIV infection
- People with an infection currently requiring intravenous (drip) antibiotics or other intravenous medication
- People with a known history of mental illness or substance abuse who are currently experiencing symptoms or still using substances
- People with a known or suspected allergy to the study drug (Furmonertinib) or any of its ingredients
- Women who are pregnant or breastfeeding, or who plan to become pregnant during the study; or male participants whose female partners are pregnant, breastfeeding, or planning to become pregnant during the study
- People who are unlikely to be able to follow the study procedures or requirements
- People whom the trial doctors consider unsuitable to participate for any other reason
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Sheng Yang, Doctor, Cancer Hospital, CAMS
Phone: 010-87788507
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.
Primary endpoints
Central Nervous System Objective Response Rate (CNS ORR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.